AbbVie Inc.
AbbVie Announces Third-Quarter 2025 Financial Results and Raises Full-Year Guidance
Summary
AbbVie Inc. reported third-quarter 2025 financial results, showing a decrease in GAAP diluted EPS by 88.6% and adjusted diluted EPS by 38.0%. The company reported net revenues of $15.776 billion, with notable growth in its immunology and neuroscience portfolios. AbbVie also raised its full-year 2025 adjusted diluted EPS guidance range from $10.38 - $10.58 to $10.61 - $10.65. Additionally, the company announced a 5.5% increase in its quarterly cash dividend starting in February 2026.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement